Biogened SA logo

BGD - Biogened SA Share Price

PLN12.9 0.0  0.0%

Last Trade - 4:35pm

Market Cap £5.88m
Enterprise Value £n/a
Revenue £n/a
Position in Universe th / 793
Unlock BGD Revenue
Relative Strength (%)
1m -11.6%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -50.4%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 01st Jan 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
Balance Sheet
FINANCIAL BRIEF: : BIOGENED SA has not disclosed any comparablefinancial information.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


BGD Revenue Unlock BGD Revenue

Net Income

BGD Net Income Unlock BGD Revenue

Normalised EPS

BGD Normalised EPS Unlock BGD Revenue

PE Ratio Range

BGD PE Ratio Range Unlock BGD Revenue

Dividend Yield Range

BGD Dividend Yield Range Unlock BGD Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BGD EPS Forecasts Unlock BGD Revenue
Profile Summary

Biogened SA is a Poland-based company active in the healthcare sector. The Company is engaged in production and distribution of generic pharmaceuticals in psychiatry, neurology and oncology, as well as development, production and distribution of dermocosmetics and diet supplements. The Company’s product portfolio includes: Polmantis and SST Salvia Stimulating Tablets (pharmaceuticals), Dermedic, Ellexir, Herba Botanic and Novoscabin (dermocosmetics), and Fibers, Prolady, Futimal and Dermedic Caps (diet supplemenst). As of March 31, 2012, Life Science Technologies NV held an 80.92% stake in the capital.

Last Annual January 1st, 1970
Last Interim January 1st, 1970
Incorporated February 1, 2007
Public Since August 31, 2011
No. of Shareholders: n/a
No. of Employees: n/a
Sector Healthcare
Industry Pharmaceuticals
Exchange Warsaw Stock Exchange
Shares in Issue
Free Float (0.0%)
Eligible for
× ISAs
BGD Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for BGD
Upcoming Events for BGD
Wednesday 16th June, 2021 Estimate
Biogened SA Annual Shareholders Meeting
Frequently Asked Questions for Biogened SA
What is the Biogened SA share price?

As of 4:35pm, shares in Biogened SA are trading at PLN12.9, giving the company a market capitalisation of £5.88m. This share price information is delayed by 15 minutes.

How has the Biogened SA share price performed this year?

Shares in Biogened SA are currently trading at PLN12.9 and the price has moved by -38.12% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Biogened SA price has moved by -51.85% over the past year.

What are the analyst and broker recommendations for Biogened SA?

There are no analysts currently covering Biogened SA.

When will Biogened SA next release its financial results?

It is not known when Biogened SA will next release financial results.

What is the Biogened SA dividend yield?

Biogened SA does not currently pay a dividend.

Does Biogened SA pay a dividend?

Biogened SA does not currently pay a dividend.

When does Biogened SA next pay dividends?

Biogened SA does not currently pay a dividend.

How do I buy Biogened SA shares?

To buy shares in Biogened SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Biogened SA?

Shares in Biogened SA are currently trading at PLN12.9, giving the company a market capitalisation of £5.88m.

Where are Biogened SA shares listed? Where are Biogened SA shares listed?

Here are the trading details for Biogened SA:

Country of listing: Poland
Exchange: WSE
Ticker Symbol: BGD
What kind of share is Biogened SA?

We were not able to load our ranking data for Biogened SA

Is there a Biogened SA share price forecast 2021?

We were not able to load any forecast data for Biogened SA.

How can I tell whether the Biogened SA share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Biogened SA. Over the past six months, the relative strength of its shares against the market has been -13.12%. At the current price of PLN12.9, shares in Biogened SA are trading at -0.83% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Biogened SA PE Ratio?

We were not able to find PE ratio data for Biogened SA.

Who are the key directors of Biogened SA?

Biogened SA's management team is headed by:

Barbara Bieganska - VMG
Andrzej Grzegorzewski - CMG
Anna Kowalska - SUB
Urszula Grzegorzewska - CSU
Dorota Skorupa - CAO
Andrzej Mozyszek - SUB
Elzbieta Mikolajczyk - SUB
Sebastian Kostecki - SUB
Who are the major shareholders of Biogened SA?

Here are the top five shareholders of Biogened SA based on the size of their shareholding:

Enrav FIZAN Corporation
Percentage owned: 40.9% (1.00m shares)
Life Science Technologies NV Corporation
Percentage owned: 36.93% (907k shares)
Bioniq Ltd Corporation
Percentage owned: 16.28% (400k shares)
PZU Asset Management SA Investment Advisor
Percentage owned: 2.27% (55.7k shares)
PZU FIO Energia Medycyna Ekologia Mutual Fund
Percentage owned: 2.27% (55.7k shares)
Similar to BGD
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.